Anavex Life Sciences Corp. (AVXL)
Oxford Ledge is still expanding full research coverage of AVXL. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Anavex develops precision-medicine treatments for central nervous system diseases by activating sigma-1 receptors to restore cellular health.
SEC filings
- 8-K Delisting / transfer of listing; Other material event; Financial statements and exhibits 2026-05-22
- 8-K Departure/election of directors or officers 2026-05-15
- 8-K Departure/election of directors or officers; Financial statements and exhibits 2026-05-06
- 8-K Other material event; Financial statements and exhibits 2026-03-25
- 8-K Departure/election of directors or officers; Regulation FD disclosure; Financial statements and exhibits 2026-02-25
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for AVXL. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open AVXL in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.